Zero Candida Technologies Inc. (ZCT) Opens the Market
Toronto, Ontario--(Newsfile Corp. - November 25, 2024) - Eli Ben-Haroosh, Co-Founder and Chief Executive Officer, Zero Candida Technologies Inc. (TSXV: ZCT) ("Zero Candida" or the "Company"), joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange, to open the market to celebrate the Company's new listing on the TSX Venture Exchange.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=4Rj-qOUi3-s
Zero Candida Technologies, Inc. (ZCT), is a medical device company bringing female healthcare into the 21st century. They are transforming the treatment of Vulvo-Vaginal Candidiasis ("VVC"), which affects 75% of women worldwide, often recurrent and increasingly drug-resistant with current treatments failing to address the root cause effectively. Free from chemicals and side effects, their AI-driven tampon-like device enables real-time data collection and transmission to physicians for personalized, at-home treatment. Beyond VVC, ZCT aims to revolutionize gynecology, improving access for underserved populations and advancing hybrid medicine.
Please refer to the Company's website here.
MEDIA CONTACT:
Victoria Gamble
Corporate Development Consultant
[email protected]
416-706-0332
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231280
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First-of-its-Kind: Ontario Human Rights Commission, Peel Regional Police, and Peel Police Service Board Sign Agreement to Address Systemic Racism
- iTrustCapital Now Offers Stocks and ETFs Across All Accounts, Becoming the Most Comprehensive Multi-Asset Investing Platform
- NationWide Self Storage Launches Business Storage Advantage Program to Help BC Businesses Save on Storage
Create E-mail Alert Related Categories
Newsfile, Press ReleasesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share